News | September 05, 2013

ITC Nexus Acquires Accumetrics

September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing, announced it has acquired Accumetrics, a specialist in assessing patient response to all major antiplatelet therapies. Terms of the transaction were not disclosed.

ITC develops, manufactures and markets the Hemochron product line, a market-leading POC system used to measure clotting activity for patients undergoing anticoagulation therapy. Accumetrics develops, manufactures and markets the VerifyNow product line, a market-leading POC system used to measure platelet reactivity following antiplatelet therapies, including ADP receptor antagonists and aspirin.

"ITC has a history of innovation and leadership in point-of-care coagulation testing, and Accumetrics is a pioneer and leader in point-of-care platelet function testing," said John Sperzel, CEO of ITC. "The combination of ITC's Hemochron and Accumetrics' VerifyNow product lines creates a leading hospital-based POC cardiovascular diagnostics business."

"Accumetrics has played a leading role in the development of the antiplatelet monitoring market. The performance of the VerifyNow system has been demonstrated in numerous clinical studies," said Accumetrics CEO Timothy I. Still. "I am confident that combining Accumetrics with ITC provides the best opportunity to accelerate the global adoption of the VerifyNow system."

Sperzel will serve as CEO of the combined company and Greg Tibbitts, CFO of Accumetrics, will serve as CFO of the combined company. Now that the transaction has closed, the process of integrating the ITC and Accumetrics businesses will begin immediately and the leadership teams will work closely to ensure a seamless transition for customers.

The combined company will assume a new name, Accriva Diagnostics, and its corporate headquarters will be established in San Diego.

For more information: www.itcmed.com, www.accumetrics.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
Overlay Init